SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desks quarterly earnings beat and stronger-than-expected outlook, alongside an expanded share-repurchase authorization, sparked a sharp rally. Traders are divided on whether it signals a turnaround and could pressure short sellers or whether flat-to-declining sales, margin pressure and cautious management commentary justify the rallys fade.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors HOPE-3 cardiac results receiving an American Heart Association research award has renewed attention ahead of the FDAs November 22 decision on deramiocel. Traders see the recognition as support for the cardiac data, while others note it does not resolve FDA concerns; the pending upper-limb indication remains the central approval catalyst, with the advisory committees negative vote focused on cardiomyopathy.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zetas earnings beat and raised full-year guidance are driving attention, with traders highlighting strong growth and improving cash generation. The bullish results were met with sharp after-hours swings and debate over whether the stocks reaction reflects profit-taking or a sell the news response.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Twos quarterly results and unchanged fiscal-year outlook are being weighed against the imminent GTA VI launch and managements description of pre-orders as exceptional. Traders are divided over whether the softer bookings outlook and high expectations could pressure shares or whether GTA VIs demand and future online spending support the bullish case.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs quarterly results are driving attention: revenue and backlog growth drew bullish reactions, but an earnings-per-share miss and Neutrons delay to no earlier than 2027 weighed on shares after the report. Traders are split between viewing the backlog and government financing as evidence of demand and worrying about continued losses, execution risk, and the lack of a firm Neutron launch date.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is drawing attention after a sharp rebound in gold miners alongside strength in gold. Traders are calling it a breakout and noting miners relative strength, while others caution that the rally may be stretched and question whether it can hold.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea Limited is drawing attention ahead of its quarterly earnings report, with traders focused on Shopee growth, Monees potential IPO, and spending on Sea Cloud. Bulls view the steep selloff as a buying opportunity, while bears worry about a weak quarter and rising investment costs.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Positive Phase 3 Panorama results for Definiums LSD-based DT120 in generalized anxiety disorder are driving attention, after the study met its primary and key secondary endpoints. Traders are celebrating another clinical win and a stronger potential FDA filing case, while some see a sell-the-news reaction and remain cautious about valuation and eventual commercialization.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers quarterly results and reduced profit outlook are driving attention: an unexpected loss and sharply compressed margins overshadowed strong revenue growth, fueling the selloff. Traders are split between concerns about near-term profitability and the companys branded weight-loss drugs and expansion plans, with some bulls pointing to longer-term growth potential.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs quarterly results are driving attention, with traders weighing a revenue miss amid weaker Bitcoin prices against an EPS beat largely tied to unrealized digital-asset gains, debt reduction and a new buyback authorization. Optimism about its AI/HPC pivot and Exaion contract is tempered by frustration that larger site leases remain unsigned and doubts about execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioCrysts quarterly results beat expectations and lifted its full-year revenue outlook, but ORLADEYO guidance was unchanged and investors questioned how much of the quarter reflected a pharmacy inventory build. The community is split between pointing to the companys improving commercial performance and criticizing the stocks weak reaction, with many looking to future Navenibart and Netherton data for a stronger catalyst.

BioCryst Pharma Q3 2026 Earnings Call Transcript

BioCryst Pharma (NASDAQ:BCRX) reported third-quarter financial results on Wednesday. The transcript from the company's third-quarter earnings call has been provided below.Benzinga APIs provide real-time access toread more...

BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of +40.00% and +8.32%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Bioventus (BVS) Matches Q3 Earnings Estimates

Bioventus (BVS) delivered earnings and revenue surprises of 0.00% and -4.74%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

The consensus price target hints at a 137.9% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth

Pacira BioSciences (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?

Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 Biotech Stocks to Watch as Potential Takeover Targets

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’

Equity

RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.


BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>RBC downgraded BioCryst to ‘Sector Perform’ from ‘Outperform,’ according to The Fly.</li><li>BioCryst expects revenue from Orladeyo between $625 million and $645 million in full-year 2026.</li><li>The brokerage sees longer-term potential from BioCryst’s second HAE drug, Navenibart.</li></ul>BioCryst Pharmaceuticals (BCRX) was in the spotlight on Thursday, after RBC Capital said the biotech firm faces a “challenging near-term outlook” after Pharvaris (PHVS) published strong late-stage data for hereditary angioedema (HAE) therapy.RBC downgraded BioCryst to ‘Sector Perform’ from ‘Outperform’ and lowered the price target to $11 from $13, according to The Fly. BCRX shares are currently trading near $8.The firm said Pharvaris’ experimental therapy could pressure its key hereditary angioedema drug, Orladeyo, and expects the shares to remain range-bound until new catalysts emerge.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/BCRX">BCRX shares</a> were down 8%, heading for their fifth straight session of losses.&nbsp;The stock has already shed more than 20% of its value so far over the five sessions.<h2 class="st-heading-2">Pharvaris Data Raises Competition</h2>The downgrade follows Phase 3 results for Pharvaris’ Deucrictibant XR, an experimental once-daily pill designed to prevent HAE attacks. HAE is a rare genetic condition that causes episodes of swelling in different parts of a child’s body, including the face, hands, and feet.Pharvaris said the drug reduced monthly attacks by 83% compared with placebo in its Chapter-3 study. The drug was generally well tolerated, and the company plans to begin seeking regulatory approvals in the first half of 2027.<h2 class="st-heading-2">RBC Expects Revenue Tailwinds For Orladeyo</h2>RBC believes the results could lead patients to switch away from Orladeyo and reduce the drug’s longer-term revenue to about $400 million to $450 million.The drug generated sales of over $600 million in full-year 2025, and the company expects revenue of $625 million to $645 million in 2026.Still, RBC sees longer-term potential from BioCryst’s second HAE drug, Navenibart. The Phase 3 study is fully enrolled, with six- and 12-month efficacy data expected in the third quarter of 2027.<h2 class="st-heading-2">Retail’s Take On BCRX</h2>Retail sentiment surrounding BCRX on Stocktwits remained ‘bullish’ over the past 24 hours, amid ‘high’ message volumes.One user opined that the “execution risk just rose for Navenibart.”<stembedurl>https://stocktwits.com/Cap_00/message/663973370</stembedurl>The stock has gained around 4% so far in 2026.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/brent-futures-top-105-per-barrel-as-houthis-seize-strategic-red-sea-port-opec-cuts-2026-demand-outlook/cZtagdoRJ62">&nbsp;Brent Futures Top $105 Per Barrel As Houthis Seize Strategic Red Sea Port — OPEC Cuts 2026 Demand Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.

SPDR S&P Biotech ETF

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$0.09	--	--	N/A
Q3 '26	$0.09	$0.14	52.40%	BEAT
Q2 '26	$0.15	$0.30	94.58%	BEAT
Q1 '26	$0.04	-$2.98	-6831.88%	MISSED
Q4 '25	$0.05	$1.12	2220.04%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCRX Earnings

Latest Earnings Results: Q3 '26

Historical Earnings